The global castration-resistant prostate cancer (CRPC) treatment market will grow at a CAGR of more than 9.5% during the forecast period. This market research study identifies Astellas Pharma, Johnson & Johnson, Sanofi, and Valeant as the leading players in the global castration-resistant prostate cancer (CRPC) treatment market
NEWARK, Del: During the forecast period 2023 to 2033, the Castration-Resistant Prostate Cancer (CRPC) Treatment market is expected to grow at a value of 9.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to rise up to a market valuation of US$ 28 Million. Growth of the market can be attributed to increasing prevalence of CRPC, coupled with the growing awareness and diagnosis of the disease, is one of the key drivers of this growth. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.
Another important factor driving the growth of the CRPC treatment market is the increasing use of combination therapies. By using a combination of different drugs and treatments, physicians can better target the cancer and improve treatment outcomes. For example, combining targeted therapies with immunotherapies has shown promise in early studies.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16739
One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies around the world.
Key Takeaways from the Market Study
- Castration-Resistant Prostate Cancer (CRPC) Treatment market expected to grow at a value of 9.5% CAGR during the forecast period 2023 to 2033.
- By drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
- North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
- Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
“The development of new targeted therapies, immunotherapies, and combination therapies is driving this growth, and there is significant potential for continued innovation in the years to come.” states an FMI analyst
View Complete Report@ https://www.futuremarketinsights.com/reports/castration-resistant-prostate-cancer-treatment-market
Competitive Landscape
Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation
- Sanofi, a key player in CRPC treatment market is involved in the development of other drugs for the treatment of cancer more broadly, including immunotherapies and targeted therapies.
- in 2019, Abbott announced the launch of a new clinical trial to investigate the use of their drug, ABT-199, in combination with enzalutamide (Xtandi) for the treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by inhibiting a protein called BCL-2, which is overexpressed in many cancer cells.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Castration-Resistant Prostate Cancer (CRPC) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Therapy Type (Hormonal therapy, Chemotherapy, Immunotherapy, Radiotherapy) Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor) Drug Delivery Method (Oral Route, Injectable Route) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16739
Table of Content
1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
Buy Now@ https://www.futuremarketinsights.com/checkout/16739
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at Related Reports of Healthcare domain
DNA Sequencing Services Market Size: The global DNA sequencing services market is anticipated to be valued at US$ 881.2 Million in 2022, forecast to grow at a CAGR of 6.2% to be valued at US$ 1,708.4 Million from 2022 to 2032.
Drug Discovery Enzymes Market Share: The drug discovery enzymes market is likely be worth US$ 1,776.8 million by 2032, from its projected US$ 886.6 million in 2022. A 6.5% CAGR in the market is predicted, during the forecast period.
DNA Synthesis Market Demand: The DNA synthesis market is projected at a CAGR of 7.7% during the forecast period. The market is likely to be valued at US$ 261.9 Mn in 2022 and at US$ 592.1 Mn by 2032.
Point of Care Blood Testing Devices Market Overview: The point of care blood testing devices market is forecasted to be valued at US$ 49,973.6 million by 2032, up from US$ 15,362.4 million in 2022, advancing at a CAGR of 11.3% during the forecast period.
Non-hospital-based point-of-care diagnostic products market Outlook: The demand for non-hospital-based point-of-care diagnostic products is estimated to reach US$ 33.6 Billion by 2032, with a CAGR of 9.1% during the forecast period.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, US, and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries:sales@futuremarketinsights.com
